OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
The webcast replay of the General Assembly Meeting of September 30, 2025 (in French), is available: click here
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.